RxDoctor Payments Data

Barnali Hasan, MD

Internal Medicine · Jamaica, NYNPI 1649505553

Payments from drug & device makers

$1,694in general payments, 2019–2025

Across 31 payments — averaging $54.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$814
  • AstraZeneca$268
  • Lilly USA, LLC$229
  • Novo Nordisk$158
  • Pfizer$148
  • Boehringer Ingelheim$36
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$1,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer11$814
AstraZeneca3$268
Lilly USA, LLC7$229
Novo Nordisk4$158
Pfizer3$148
Boehringer Ingelheim1$36
Exact Sciences1$26
Amgen1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,694 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$27,929
Medicare patients
13
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate65$36,954
JardianceEmpagliflozin46$29,344
OzempicSemaglutide23$22,171
KerendiaFinerenone22$13,739
EliquisApixaban20$11,437
FarxigaDapagliflozin Propanediol13$7,169
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$3,890
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,105
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,054
Atorvastatin Calcium170$791
Albuterol Sulfate HfaAlbuterol Sulfate24$704
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic11$526
Levothyroxine Sodium52$378
Metoprolol Succinate68$351
Metformin Hcl111$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$36$29,34446 claims
Novo NordiskOzempic$158$22,17123 claims
BayerKerendia$814$13,73922 claims
PfizerEliquis$148$11,43720 claims
AstraZenecaFarxiga$268$7,16913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →